Reaction

Body Temperature Abnormal reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,820 reports · 63 co-occurring drugs

As of the last recalculation, Body Temperature Abnormal appears in 1,820 FAERS reports alongside 63 co-occurring drug terms. The strongest observed disproportionality signal is MUPIROCIN CALCIUM (PRR 21.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Mupirocin Calcium	25	21.1	21.1
Mupirocin	24	20.6	20.6
Diphenhydramine Hydrochloride Capsule, Liquid Filled	36	19.6	19.7
Adrenalinum	54	15.3	15.3
Human Immunoglobulin G	25	14.0	14.1
Nicotine Polacrilex Mini	16	12.3	12.3
Nicotine Polarilex	16	12.3	12.3
Aprepitant	17	10.6	10.6
Diphenhydramine	57	10.6	10.6
Sodium Chloride Tablet	65	10.4	10.4
Sodium Chloride Tablets	65	10.4	10.4
Epinephrine	57	10.2	10.3
Mometasone Furoate	36	10.1	10.1
Fosaprepitant Dimeglumine	12	10.0	10.0
Sodium Chloride	67	10.0	10.0
Omalizumab	70	9.7	9.7
Dextrose	11	9.6	9.6
Infliximab-Dyyb	24	9.5	9.5
Dextrose Monohydrate	11	9.5	9.5
Asfotase Alfa	8	9.2	9.2
Blinatumomab	8	8.8	8.8
Aripiprazole Oral	31	8.7	8.7
Aripiprazole Orally Disintegrating	31	8.7	8.7
Fexofenadine Hcl	7	8.7	8.7
Ofatumumab	24	8.4	8.4
Lisinopril And Hydrochlorothiazide Tablets	5	7.3	7.3
Epoprostenol	8	7.0	7.0
Azelastine	10	6.4	6.4
Desoximetasone	10	6.0	6.0
Naproxen Sodium Tablet, Coated	7	5.9	5.9
Naproxen Sodium, Coated Tablets	7	5.9	5.9
Naproxen Sodium 220Mg	7	5.9	5.9
Ifosfamide	10	5.3	5.3
Fexofenadine Hydrochloride	10	5.3	5.3
Rasagiline Mesylate	5	5.1	5.2
Tiotropium Bromide Inhalation Spray	5	5.1	5.1
Dabrafenib	9	4.9	4.9
Nicotine Polacrilex	16	4.8	4.8
Nicotine	16	4.6	4.6
Azacitidine For	7	4.4	4.4
Pegfilgrastim	37	4.4	4.4
Ivacaftor	3	4.3	4.3
Trifluridine And Tipiracil	4	4.3	4.3
Ravulizumab	5	4.2	4.2
Brexpiprazole	6	4.1	4.1
Venetoclax	22	4.1	4.1
Vortioxetine	6	4.0	4.0
Eculizumab	19	4.0	4.0
Benralizumab	7	4.0	4.0
Lumacaftor And Ivacaftor	3	4.0	4.0
Trametinib	8	3.8	3.8
Agalsidase Beta	3	3.7	3.7
Axicabtagene Ciloleucel	3	3.5	3.5
Fremanezumab-Vfrm	3	3.0	3.0
Rimegepant Sulfate	3	2.7	2.7
Cinacalcet Hydrochloride	11	2.7	2.7
Palivizumab	3	2.2	2.2
Lifitegrast	3	2.1	2.1
Erenumab-Aooe	10	2.1	2.1
Relugolix	4	1.9	1.9
Nirmatrelvir And Ritonavir	9	1.9	1.9
Galcanezumab-Gnlm	4	1.5	1.5
Evolocumab	20	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.